Liberman Paulina, Berkenstock Meghan K, Burkholder Bryn M, Chaon Benjamin C, Thorne Jennifer E
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Departamento de Oftalmología, Facultad de Medicina, Pontificia Universidad Católica De Chile, Santiago, Chile.
Ocul Immunol Inflamm. 2021 Nov 17;29(7-8):1564-1568. doi: 10.1080/09273948.2020.1749857. Epub 2020 May 14.
: To report the outcomes of the escalation of adalimumab (ADA) dose for refractory ocular inflammatory diseases.: A retrospective case series of 15 patients (29 eyes) diagnosed with ocular inflammatory disease, including uveitis and scleritis, which was not adequately controlled with standard, every other week ADA dosing, leading to an escalation to weekly dosing.: Ten of fifteen patients escalated to weekly ADA achieved control of their inflammation; neither of the two patients increased for control of cystoid macular edema (CME) had resolution and required regional corticosteroids. One patient discontinued weekly ADA due to serious infection. The median length of follow up was 12 months.: Our series suggests that the escalation of ADA can be a useful strategy for treating recalcitrant ocular inflammation, but may not be adequate to treat refractory CME.
报告阿达木单抗（ADA）剂量增加用于治疗难治性眼部炎性疾病的疗效。：一项回顾性病例系列研究，纳入15例（29只眼）被诊断为眼部炎性疾病（包括葡萄膜炎和巩膜炎）的患者，这些患者采用标准的每两周一次ADA给药方案未能得到充分控制，因此剂量增加至每周一次。：15例剂量增加至每周一次ADA的患者中有10例炎症得到控制；为控制黄斑囊样水肿（CME）而增加剂量的2例患者均未缓解，需要局部使用皮质类固醇。1例患者因严重感染停用每周一次的ADA。中位随访时间为12个月。：我们的系列研究表明，增加ADA剂量可能是治疗顽固性眼部炎症的有效策略，但可能不足以治疗难治性CME。
